Public Policy

In 2018, the U.S. Food and Drug Administration (FDA) invited comments on its intention to exempt a list of class II devices from premarket notification requirements, including tests assessing genetic health risks. ASHG responded to this request for comment by outlining its support for regulation that brings scientifically valid, evidence-based tests to market, and expressing... Read More

This month, we check in with Barbara Evans to discuss her commentary on the individual right of access to genomic data. Read More

We sat down with Nikki Meadows, PhD, ASHG/NHGRI Genetics & Public Policy Fellow, to find out more about her background and interest in science policy. Read More

In 2017, ASHG and 10 international organizations published a position statement on human germline genome editing in The American Journal of Human Genetics. The statement recommended against genome editing culminating in human pregnancy, supported publicly funded in vitro research into its potential clinical applications, and outlined scientific and societal steps necessary before implementation of such... Read More

Posted by: Derek Scholes, PhD, ASHG Director of Science Policy As you may have heard, a bill called the Preserving Employee Wellness Programs Act (H.R.1313) was introduced last month in the U.S. House of Representatives. If passed, this bill would fundamentally undermine the privacy protections of the Genetic Information Nondiscrimination Act (GINA), a 2008 law... Read More